Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ATPase phospholipid-transporting 9B (ATP9B) is a member of the P4-ATPase family, functioning as an ATP-dependent phospholipid "flippase" that translocates specific phospholipids from the exoplasmic to the cytoplasmic leaflet of cellular membranes[1][2][4]. Unlike most other P4-ATPases, ATP9B localizes to the trans-Golgi network and can exit the endoplasmic reticulum independently of CDC50 proteins[2][4]. ATP9B forms homo- or heteromeric complexes (notably with ATP9A) to mediate efficient vesicular trafficking, particularly in exocytic pathways between the Golgi and plasma membrane[4]. The gene is implicated in certain neurodevelopmental and hepatic disorders, and polymorphisms may modulate susceptibility to additional conditions such as skin diseases, but ATP9B is not currently a direct drug target, nor are clinically approved drugs known to interact with it[1][2][4].
Not applicable or none known (no known targeting drugs as of current evidence)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ATPase phospholipid-transporting 9B (ATP9B).